For information on treatments and vaccines for COVID-19, including those under evaluation by the CHMP:

The CHMP meets once per month. Its evaluations of marketing authorisation applications submitted through the centralised procedure provide the basis for authorisation of medicines in Europe.

Monthly lists of medicines under evaluation by the CHMP are available dating back to 2012. They contain the international non-proprietary names (INN) and therapeutic areas of innovative medicines. The INN contains only the active moiety for generic medicines and biosimilar medicines, with no information on salt, ester or derivative. The lists are available in Excel format from February 2021 to support data sorting and filtering. 

The CHMP's independent recommendations on medicine for human use are based on a comprehensive scientific evaluation of data. For information on how EMA evaluates medicines and the CHMP's role in the authorisation of medicines in the EU:

Monthly lists - 2024

Applications for new human medicines under evaluation: January 2024

Applications for new human medicines under evaluation: February 2024

Applications for new human medicines under evaluation: March 2024

Monthly lists - 2023

Applications for new human medicines under evaluation by the CHMP: December 2023

Applications for new human medicines under evaluation by the CHMP: November 2023

Applications for new human medicines under evaluation by the CHMP: October 2023

Applications for new human medicines under evaluation by the CHMP: September 2023

Applications for new human medicines under evaluation by the CHMP: August 2023

Applications for new human medicines under evaluation by the CHMP: July 2023

Applications for new human medicines under evaluation by the CHMP: June 2023

Applications for new human medicines under evaluation by the CHMP: May 2023

Applications for new human medicines under evaluation by the CHMP: April 2023

Applications for new human medicines under evaluation by the CHMP: March 2023

Applications for new human medicines under evaluation by the CHMP: February 2023

Applications for new human medicines under evaluation by the CHMP: January 2023

Monthly lists - 2022

Applications for new human medicines under evaluation by the CHMP: December 2022

Applications for new human medicines under evaluation by the CHMP: November 2022

Applications for new human medicines under evaluation by the CHMP: October 2022

Applications for new human medicines under evaluation by the CHMP: September 2022

Applications for new human medicines under evaluation by the CHMP: August 2022

Applications for new human medicines under evaluation by the CHMP: July 2022

Applications for new human medicines under evaluation by the CHMP: June 2022

Applications for new human medicines under evaluation by the CHMP: May 2022

Applications for new human medicines under evaluation by the CHMP: April 2022

Applications for new human medicines under evaluation by the CHMP: March 2022

Applications for new human medicines under evaluation by the CHMP: February 2022

Applications for new human medicines under evaluation by the CHMP: January 2022

Monthly lists - 2021

Applications for new human medicines under evaluation by the CHMP: December 2021

Applications for new human medicines under evaluation by the CHMP: November 2021

Applications for new human medicines under evaluation by the CHMP: October 2021

Applications for new human medicines under evaluation by the CHMP: September 2021

Applications for new human medicines under evaluation by the CHMP: August 2021

Applications for new human medicines under evaluation by the CHMP: July 2021

Applications for new human medicines under evaluation by the CHMP: June 2021

Applications for new human medicines under evaluation by the CHMP: May 2021

Applications for new human medicines under evaluation by the CHMP: April 2021

Applications for new human medicines under evaluation by the CHMP: March 2021

Applications for new human medicines under evaluation by the CHMP: February 2021

Applications for new human medicines under evaluation by the CHMP: January 2021

Topics

How useful do you find this page?

Average: